HomeCONGRESS

CONGRESS

View Category
Day 1

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated...
solaci -
Learn More
Day 1

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor...
solaci -
Learn More
Day 1

ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient

The aim of the study was to show a reduction in LDL cholesterol with the use of...
solaci -
Learn More
Day 1

SOLID-TIMI 52: Darapladib to reduce new cardiovascular events after myocardial infarction

This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days...
solaci -
Learn More
Day 1

MORE-CRT: Cardiac resynchronization with quadrupole electrode reduces complications

In approximately 10% of patients for resynchronization therapy implantation of ventricular lead is not possible for anatomical...
solaci -
Learn More
Day 1

POPE-2: Colchicine to prevent pericardial effusion after cardiac surgery

The incidence of asymptomatic pericardial effusion after cardiac surgery is high. The aim of this study was...
solaci -
Learn More
Day 1

NECTAR HF: Chronic vagal stimulation for heart failure with low ejection fraction

The increased sympathetic activity and reduced parasympathetic tone are important pathophysiological contributors to the progression of heart...
solaci -
Learn More
Day 1

CONFIRM HF: Is it safe to replace intravenous iron in patients with chronic heart failure

This study aimed to assess whether iron replacement versus placebo could improve physical activity in patients with...
solaci -
Learn More